Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFG87U
|
|||
| Drug Name |
MEDI6570
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 2 | [1] | |
| Coronary heart disease [ICD-11: BA80.Z; ICD-9: 414] | Phase 2 | [1] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lectin-like oxidized LDL receptor (OLR1) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04610892) A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AstraZeneca | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.